Retraction Watch

‘We apologize again for the inadvertent mistakes during the assembly of data due to our carelessness’

Baodi Clinical College of Tianjin Medical University

Last December, Elisabeth Bik notified journals about 45 articles by a researcher in China which struck her as suspicious. Within weeks, one of those journals — DNA and Cell Biology — had retracted the paper she’d flagged.

That reassuringly brisk response appears to have been an anomaly in the case of Hua Tang, of Tianjin Medical University in China. Only two other retractions have followed, by our count (Tang had a retraction in 2020, bringing his total so far to four). However, FEBS Letters, which published three articles by Tang that Bik had identified as problematic, has now issued expressions of concern for the papers.

The notices for the articles, which appeared between 2011 and 2014, raise questions about the “data integrity” in the work. Here’s the one for “Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells,” from 2014:

An exercise in frustration: A researcher is impersonated

The other day, Jamie Burr, an exercise physiologist in Canada, received a curious email from an overseas colleague. The researcher wanted to know if Burr, of the University of Guelph, had written a particular article.

Burr wondered:

Why are they questioning if I wrote something?

Turns out, something was real shady with the slim article.

Most of problematic articles flagged in Japanese university’s investigation remain unflagged nearly a year later

Ten months after a misconduct investigation into the work of a researcher in Japan four of his papers found to have serious issues have yet to be retracted.

According to an August 2020 report from National University Corporation Osaka University and National Cerebral and Cardiovascular Center Hospital about its investigation of Takashi Nojiri:

Pulp fiction: Japanese university revokes two dentistry PhDs in case involving two dozen retractions

The misconduct case of an endodontics researcher in Japan who already has lost at least 24 papers for data problems has claimed two more casualties: the PhD theses of a pair of scientists he once helped train.

As we reported last year, Nobuaki Ozeki, who retired from Aichi Gakuin University in 2018, was found to have misused images, fabricated data and recycled text in 22 papers, 21 of which by our count have now been retracted. Ozeki’s total retraction count is 24, as three papers not identified in the investigation have also been retracted.

Now, we’ve learned that the university has revoked the doctoral degrees of two of Ozeki’s co-authors, Hideyuki Yamaguchi and Rie (Satoe) Kawai. Both researchers received their degrees in March 2016.

Weekend reads: Biotech CEO on leave after allegations on PubPeer; a researcher disavows his own paper; plagiarism here, there, and everywhere

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance.

The week at Retraction Watch featured:

‘A costly mistake’ prompts retraction of paper on hair loss
Widely covered paper on ranitidine-cancer link retracted
Paper by former NIH researcher alleging ‘Ponzi schemes’ by government, pharma retracted
Elsevier glitch prompts temporary removal of critique of review on race and heart disease
‘Galling’: Journal scammed by guest editor impersonator

Our list of retracted or withdrawn COVID-19 papers is up to 128.

Here’s what was happening elsewhere (some of these items may be paywalled, metered access, or require free registration to read):

‘Galling’: Journal scammed by guest editor impersonator

An Elvis impersonator, via Metro Library and Archive

It just keeps happening.

For at least the fourth time in two years, a journal has been scammed by someone impersonating a guest editor. The latest: Behaviour & Information Technology, a Taylor & Francis title, has retracted an entire special issue — at least 10 articles published between 2019 and 2020 — because the guest editor “was impersonated by a fraudulent entity.”

As the retraction notices for the 10 papers report:

Elsevier glitch prompts temporary removal of critique of review on race and heart disease

A timing glitch prompted the temporary removal of a letter to the editor calling out a previously published study for “perpetuating historical harms” through its framing of race and ethnicity.

The letter, “Race is not a risk factor: Reframing discourse on racial health inequities in CVD prevention,” appeared online in April in the American Journal of Preventive Cardiology, an Elseiver property. It came in response to a review article, published the month before, titled “Ten things to know about ten cardiovascular disease risk factors.”

As the abstract of the review stated:

Paper by former NIH researcher alleging ‘Ponzi schemes’ by government, pharma retracted

Mahin Khatami, a former researcher with the U.S. National Institutes of Health who has argued in print that cancer results from ‘dark energy’ and that the government and the pharmaceutical industry are collaborating in ‘scientific/medical Ponzi schemes’ to keep people sick, has lost a paper to retraction.

As we reported last fall, Robert Speth, a pharmacy science researcher at Nova Southeastern University in Ft. Lauderdale, Fla., has been urging Clinical & Translational Medicine (CTM) to retract Khatami’s articles — and one in particular — for what is now more than two years.

In mid-October a spokesperson for Wiley, which publishes the journal, told us that she was trying to get more information from the editors about why Khatami’s bizarre paper was acceptable material.

Widely covered paper on ranitidine-cancer link retracted

A paper linking the use of a wildly popular drug for heartburn to cancer has been retracted after the authors concluded that their widely touted finding appears to have resulted from a hiccup in the way they conducted their testing.

The 2016 article, in Carcinogenesis, has played a minor role in an ongoing class action lawsuit against the makers of ranitidine (sold as Zantac, among other brand names) claiming that use of the medication has caused cancer in more than 100,000 plaintiffs. And it was a key citation in a 2019 petition to the FDA urging that such drugs be recalled.

The FDA has been investigating contamination of ranitidine and a related drug with NDMA, a known human carcinogen at high doses. On April 1, 2020, the agency announced that, although its tests did not find concerning levels of NDMA in “many” of the samples it tested, it was recalling all products that contain ranitidine:

‘A costly mistake’ prompts retraction of paper on hair loss

Image by Martin Slavoljubovski from Pixabay

A “costly mistake” has led to the retraction of a paper by a team of dermatology researchers in West Virginia who failed to obtain permission to use the data in their study for the specific purpose for which it was used.

The article, “Association Between Alopecia Areata and Natural Hair Color Among White Individuals,” which appeared in March 2021 in JAMA Dermatology, was a case-control study based on data from the UK Biobank — a large repository of medical and genetic data from people in the United Kingdom. The senior author on the article was Michael Kolodney, the chair of the department of dermatology at West Virginia University School of Medicine in Morgantown.

In fact, Kolodney and his colleagues had produced two articles using data from the biobank: one on alopecia areata — an autoimmune condition that causes relatively early-onset hair loss — and another that linked baldness to an increased risk of Covid-19 in men. The Covid research was published in November 2020 as a letter to the editor in the Journal of the American Academy of Dermatology.

The Covid paper remains intact. But as the retraction notice indicates, the folks at UK Biobank hadn’t granted Kolodney’s group permission to publish the alopecia findings:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: